News
Relevance section written by JCO Associate Editor Thomas E. Stinchcombe, MD. Tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE) molecule, binds both DLL3 on cancer cells and CD3 on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback